Validating survivin as a cancer therapeutic target

@article{Altieri2003ValidatingSA,
  title={Validating survivin as a cancer therapeutic target},
  author={Dario C. Altieri},
  journal={Nature Reviews Cancer},
  year={2003},
  volume={3},
  pages={46-54}
}
Acquisition of the ability to evade cellular suicide, or apoptosis, is one of the master switches that contributes to cellular transformation and, ultimately, to invasive cancer. Much has been learned about the molecular organization of apoptotic pathways and their regulators, but the identification and validation of translational targets for apoptosis-based cancer therapy has posed a great challenge. Survivin is an attractive candidate for cancer therapy, so what is its potential applicability… CONTINUE READING
Highly Influential
This paper has highly influenced 19 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

From This Paper

Figures, tables, and topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
Showing 1-10 of 553 extracted citations

Chemically synthesized human survivin does not inhibit caspase-3.

Protein science : a publication of the Protein Society • 2008
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 128 references

A role for survivin in chemoresistance of endothelial cells mediated by VEGF

J Tran
Proc. Natl Acad. Sci. USA 99, • 2002

An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2002

Similar Papers

Loading similar papers…